Dr Reddy’s Laboratories and TR-Pharm today announced a strategic agreement involving three biosimilar products. A total of three products will be registered and subsequently commercialised as a part of this agreement by TR-Pharm in Turkey.
TR-Pharm will also manufacture the drug substance and drug product upon completion of its facility investment. Mehmet Goker, General Manager, of the company said: “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country”.